Patient Groups Seek Drug Access Protections In State Exchange Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
In comments, a group of 151 patient organizations requests that HHS adapt a number of Medicare Part D requirements for private insurance plans that will be available through state exchanges under the Affordable Care Act, such as broad formulary coverage and timelines for adding new drugs to formularies and responding to formulary appeals.
You may also be interested in...
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.